MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Status Recruiting

Clinical Trial Summary

This is a phase l/ll multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. The trial consists of 2 parts: Part I and Part II. In total approximately 48 patients will be included in Part I of the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

Clinical Trial Description

The Part I (Phase I) will evaluate the safety of the MB-CART19.1 and determine the recommended dose levels for the Part II (Phase II) efficacy evaluation in each of the three disease cohorts. Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1 and in Cohort 3 with Dose Level 2, sparing Dose Level 1 (see figure 1). Each of the cohorts will evaluate the safety of MB-CART19.1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable. Cohort 3 will Start with Dose Level 2. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. DLT will be evaluated within 4 weeks after the infusion of MB-CART19.1. An interval of at least 28 days between the treatment of the first and the second patient in each dose level (and in each cohort) is mandatory. Part II (Phase II) will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively. After review of completed day 28 safety and efficacy data within Part I (Phase I) by the SMB, the design of Phase II, specifically the number and types of Phase II cohorts and the recommended dose level(s) for Phase II will be determined and thus, the number of patients to be treated will be calculated. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia Recurrent
B-cell Lymphoma Recurrent
B-cell Lymphoma Refractory
Chronic Lymphocytic Leukemia Recurrent
Chronic Lymphocytic Leukemia Refractory
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Lymphoma, B-Cell
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence

Clinical Trial Details

NCT number	NCT03853616
Study type	Interventional
Source	Miltenyi Biomedicine GmbH
Contact	Alisa Yakushina
Phone	+4916098973562
Email	Alisa.yakushina@miltenyi.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 26, 2018
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting	`NCT03664635` - MB-CART20.1 Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05360238` - Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	Phase 1/Phase 2
Not yet recruiting	`NCT04303247` - CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL	Early Phase 1
Recruiting	`NCT05318963` - Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma	Phase 1
Active, not recruiting	`NCT04531046` - Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation	Phase 2
Not yet recruiting	`NCT05705570` - A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies	Phase 1
Active, not recruiting	`NCT04304040` - A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma	Phase 1/Phase 2
Not yet recruiting	`NCT05909098` - Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04747093` - Induced-T Cell Like NK Cells for B Cell Malignancies	Phase 1/Phase 2
Completed	`NCT05130489` - CAR T Cell Therapy Related Cardiovascular Outcomes
Recruiting	`NCT01786018` - Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas	Phase 2
Recruiting	`NCT06220097` - Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies	Phase 2
Active, not recruiting	`NCT04214886` - CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies	Phase 1
Completed	`NCT01535989` - Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.